Moderna insider plans $5.8M stock sale in 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Moderna, Inc. (MRNA) insider Stephen Hoge filed a Rule 144 notice planning to sell 40,294 shares of common stock, with an aggregate market value of $5,807,745.84, through Fidelity Brokerage Services LLC, with an expected sale date of September 14, 2026 on NASDAQ.
The planned sale is tied to a stock option exercise with cash payment to the issuer. Moderna reports 399,235,889 shares outstanding, which is a baseline figure, not the amount being sold. Hoge also sold 53,336 shares on June 15, 2026 for $2,739,870.32 and 53,336 shares on July 15, 2026 for $3,605,513.60.
Key Figures
Key Terms
Rule 144 regulatory
stock option exercise financial
aggregate market value financial
Form 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What aggregate market value is associated with Stephen Hoge’s planned Moderna (MRNA) sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.